Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Gorilla Technology
GRRR
US Stock MarketDetailed Quotes
HALO Halozyme Therapeutics
- 61.450
- +0.010+0.02%
Close Mar 11 16:00 ET
- 61.450
- 0.0000.00%
Post 20:01 ET
7.57BMarket Cap17.92P/E (TTM)
62.390High60.646Low1.22MVolume61.240Open61.440Pre Close74.97MTurnover1.00%Turnover Ratio17.92P/E (Static)123.15MShares65.53352wk High20.80P/B7.48BFloat Cap37.73052wk Low--Dividend TTM121.76MShs Float65.533Historical High--Div YieldTTM2.84%Amplitude1.410Historical Low61.545Avg Price1Lot Size
Halozyme Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 23.29%479.06M | 74.36%178.47M | -12.87%115.38M | -16.53%55.79M | 48.83%129.43M | 61.83%388.57M | 24.14%102.35M | 90.15%132.41M | 66.17%66.84M | 81.94%86.96M |
| Net income from continuing operations | 57.71%444.09M | 60.46%137.01M | 67.42%137.01M | 24.74%93.25M | 93.92%76.82M | 39.31%281.59M | 47.98%85.39M | 32.78%81.84M | 229.53%74.75M | -34.09%39.62M |
| Operating gains losses | 149.10%1.52M | -258.51%-149K | --0 | --1.68M | ---7K | -67.08%611K | 91.84%94K | --0 | ---- | ---- |
| Depreciation and amortization | -4.18%81.31M | -1.34%20.42M | -11.78%20.36M | -1.44%20.33M | -1.23%20.21M | 70.94%84.86M | 190.88%20.69M | -20.97%23.08M | 64.42%20.63M | 2,529.43%20.46M |
| Deferred tax | -98.46%532K | -262.28%-15.29M | -96.99%292K | 23.76%14.24M | -66.68%1.29M | -13.75%34.51M | -35.79%9.42M | -62.25%9.7M | 186.53%11.51M | -70.03%3.87M |
| Other non cash items | 281.95%8.42M | -63.92%2.05M | 118.03%2.2M | 842.66%2.12M | -4.87%2.05M | -166.78%-4.63M | 777.43%5.68M | -313.02%-12.17M | -203.25%-286K | 645.67%2.16M |
| Change In working capital | -130.86%-89.28M | 197.21%25.37M | -344.22%-53.94M | -69.70%-82.26M | 56.04%21.56M | 55.01%-38.67M | -413.80%-26.1M | 137.06%22.09M | -566.37%-48.48M | 143.62%13.81M |
| -Change in receivables | -2,123.57%-74.25M | -34.51%-22.71M | -346.84%-71.22M | 63.84%-18.62M | 5.86%38.31M | 96.02%-3.34M | -117.73%-16.89M | 165.67%28.85M | -444.07%-51.5M | 258.81%36.19M |
| -Change in inventory | -150.64%-67.38M | -625.94%-7.73M | -45.51%1.98M | 13.48%-21.4M | -454.94%-40.23M | -53.79%-26.88M | 149.88%1.47M | 165.94%3.63M | -61.44%-24.74M | -215.12%-7.25M |
| -Change in prepaid assets | 30.70%5.36M | 568.03%5.62M | 555.42%38.48M | -994.47%-43.54M | -46.01%4.8M | 145.21%4.1M | -122.68%-1.2M | -67.66%-8.45M | 3,323.84%4.87M | 196.87%8.88M |
| -Change in payables and accrued expense | 474.57%46.99M | 629.44%50.19M | -1,088.21%-23.18M | -94.30%1.3M | 177.83%18.69M | -151.14%-12.55M | -3,007.67%-9.48M | 61.85%-1.95M | -35.22%22.89M | -299.43%-24.01M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 23.29%479.06M | 74.36%178.47M | -12.87%115.38M | -16.53%55.79M | 48.83%129.43M | 61.83%388.57M | 24.14%102.35M | 90.15%132.41M | 66.17%66.84M | 81.94%86.96M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -171.10%-262.72M | 455.57%29.48M | -100.70%-167.48M | -176.44%-42.04M | -37.43%-82.68M | 80.10%-96.91M | -374.86%-8.29M | -8,178.77%-83.45M | 112.64%54.99M | -22.02%-60.16M |
| Net PPE purchase and sale | 30.06%-10.7M | -17.57%-3.05M | 48.47%-1.52M | -259.09%-2.58M | 68.84%-3.55M | -217.96%-15.29M | -10.75%-2.6M | -192.06%-2.94M | 267.67%1.62M | -2,221.84%-11.38M |
| Net business purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | -208.80%-252.03M | 671.24%32.53M | -106.15%-165.97M | -173.93%-39.46M | -62.21%-79.14M | -116.62%-81.62M | 39.33%-5.7M | ---80.51M | -90.28%53.37M | 0.06%-48.79M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -171.10%-262.72M | 455.57%29.48M | -100.70%-167.48M | -176.44%-42.04M | -37.43%-82.68M | 80.10%-96.91M | -374.86%-8.29M | -8,178.77%-83.45M | 112.64%54.99M | -22.02%-60.16M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 46.36%-218.86M | 1.40%-246.42M | 352.60%18.56M | 287.65%9.48M | 99.70%-489K | -212.59%-407.99M | -4,048.81%-249.92M | 133.07%4.1M | -99.33%2.45M | -26,480.45%-164.61M |
| Net issuance payments of debt | --0 | --0 | --0 | --0 | --0 | -102.16%-13.48M | --0 | --0 | --0 | ---13.48M |
| Net common stock issuance | 37.87%-250M | 0.91%-250M | --0 | --0 | --0 | -101.19%-402.38M | -25,229,900.00%-252.3M | --0 | --0 | ---150.08M |
| Proceeds from stock option exercised by employees | 295.22%31.14M | 50.63%3.59M | 352.60%18.56M | 287.65%9.48M | 53.34%-489K | -43.92%7.88M | -65.85%2.38M | 55.58%4.1M | -35.99%2.45M | -267.95%-1.05M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 46.36%-218.86M | 1.40%-246.42M | 352.60%18.56M | 287.65%9.48M | 99.70%-489K | -212.59%-407.99M | -4,048.81%-249.92M | 133.07%4.1M | -99.33%2.45M | -26,480.45%-164.61M |
| Net cash flow | ||||||||||
| Beginning cash position | -49.56%118.37M | -43.73%154.32M | -15.06%187.86M | 69.92%164.63M | -49.56%118.37M | 96.86%234.7M | 85.72%274.23M | 141.89%221.17M | -18.13%96.88M | 96.86%234.7M |
| Current changes in cash | 97.83%-2.52M | 75.32%-38.47M | -163.22%-33.55M | -81.30%23.24M | 133.57%46.26M | -200.74%-116.33M | -279.07%-155.86M | -5.63%53.06M | 561.96%124.28M | -15,489.59%-137.81M |
| End cash Position | -2.13%115.85M | -2.13%115.85M | -43.73%154.32M | -15.06%187.86M | 69.92%164.63M | -49.56%118.37M | -49.56%118.37M | 85.72%274.23M | 141.89%221.17M | -18.13%96.88M |
| Free cash flow | 25.47%468.37M | 75.84%175.42M | -12.06%113.86M | -22.28%53.21M | 66.54%125.88M | 58.64%373.28M | 24.53%99.76M | 88.65%129.47M | 74.40%68.47M | 59.78%75.59M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |